Apoptosis of inflammatory cells and their phagocytic clearance by

Apoptosis of inflammatory cells and their phagocytic clearance by phagocytes are critical for the resolution of inflammation.7 LPS triggers inflammatory responses by inducing inflammatory cytokine

production and thus influences the rate of inflammatory cell apoptosis.9,21 In this study, we focused on the role of LPS and LPS-induced inflammatory modulators in regulating phagocytosis of apoptotic cells by macrophages. We demonstrated that LPS significantly inhibited phagocytosis of apoptotic neutrophils by mouse peritoneal macrophages via LPS-driven induction of TNF-α and suppression of Gas6 production. Macrophage phagocytosis prevents apoptotic cells from undergoing secondary necrosis and releasing selleck inhibitor their histotoxic contents. As different macrophage subpopulations exhibit different phagocytic features, so macrophages at different stages of maturity.11,12,22 A recent study reported that LPS inhibits the ability of human monocyte-derived macrophages to ingest apoptotic neutrophils.13 In agreement with this report, the present study showed that LPS significantly inhibited phagocytosis of apoptotic neutrophils by mouse peritoneal macrophages. However, we found that the LPS inhibition of phagocytosis occurred learn more at an earlier time-point (8 hr) after LPS treatment than that (96 hr) reported in the previous study.13 This discrepancy may be explained by the different macrophage

types used in the two studies. We have provided evidence Dapagliflozin that LPS-mediated induction of TNF-α was partially responsible for LPS inhibition of phagocytosis. TNF-α can be rapidly released

by macrophages after stimulation with LPS, and is one of the most abundant inflammatory factors in inflamed sites.23 TNF-α is actively involved in the development of both chronic inflammation and autoimmune disease.24 Consequently, the blockade of TNF-α activity, using a neutralizing antibody or a soluble TNF-α receptor, has been shown to have a therapeutic benefit in the treatment of chronic inflammatory diseases.25 However, the mechanisms underlying the role of TNF-α in the development of chronic inflammation remain to be clarified. In the present study, we have provided convincing evidence that LPS-induced TNF-α inhibits the phagocytosis of apoptotic neutrophils by mouse peritoneal macrophages. This result suggests that excess TNF-α in inflamed tissue may result in inefficient removal of apoptotic cells. This would lead to secondary cell necrosis and damage of the surrounding tissue, which in turn will delay the resolution of inflammation. However, TNF-α does not sufficiently account or LPS inhibition of phagocytosis, because neutralization of TNF-α activity by antibodies did not completely reverse the LPS inhibitory effect. In addition, LPS inhibition of phagocytosis was also observed in TLR4−/− macrophages, which had no capacity to induce TNF-α.

Comments are closed.